Effects of hyperoxia on oxygen-related inflammation with a focus on obesity by Martinez, J.A. (José Alfredo) et al.
Review Article
Effects of Hyperoxia on Oxygen-Related Inflammation with a
Focus on Obesity
Pedro González-Muniesa,1,2,3 Laura Garcia-Gerique,1 Pablo Quintero,4 Suyen Arriaza,1
Amaya Lopez-Pascual,1 and J. Alfredo Martinez1,2,3
1Centre for Nutrition Research, Department of Nutrition, Food Sciences and Physiology, University of Navarra,
Irunlarrea 1, 31008 Pamplona, Spain
2Centro de Investigacio´n Biome´dica en Red Fisiopatologı´a de la Obesidad y Nutricio´n (CIBERobn),
Instituto de Salud Carlos III, Madrid, Spain
3Navarra’s Health Research Institute (IDISNA), 31008 Pamplona, Spain
4Departamento de Gastroenterologı´a, Facultad de Medicina, Pontificia Universidad Cato´lica de Chile,
Libertador Bernardo O’Higgins 340, Santiago, Chile
Correspondence should be addressed to J. Alfredo Martinez; jalfmtz@unav.es
Received 29 April 2015; Revised 29 July 2015; Accepted 19 August 2015
Academic Editor: Cinzia Signorini
Copyright © 2016 Pedro Gonza´lez-Muniesa et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Several studies have shown a pathological oxygenation (hypoxia/hyperoxia) on the adipose tissue in obese subjects. Additionally,
the excess of body weight is often accompanied by a state of chronic low-degree inflammation. The inflammation phenomenon is
a complex biological response mounted by tissues to combat injurious stimuli in order to maintain cell homeostasis. Furthermore,
it is believed that the abnormal oxygen partial pressure occurring in adipose tissue is involved in triggering inflammatory
processes. In this context, oxygen is used in modern medicine as a treatment for several diseases with inflammatory components.
Thus, hyperbaric oxygenation has demonstrated beneficial effects, apart from improving local tissue oxygenation, on promoting
angiogenesis, wound healing, providing neuroprotection, facilitating glucose uptake, appetite, and others. Nevertheless, an
excessive hyperoxia exposure can lead to deleterious effects such as oxidative stress, pulmonary edema, and maybe inflammation.
Interestingly, some of these favorable outcomes occur under high and low oxygen concentrations. Hereby, we review a potential
therapeutic approach to the management of obesity as well as the oxygen-related inflammation accompanying expanded adipose
tissue, based on elevated oxygen concentrations. To conclude, we highlight at the end of this review some areas that need further
clarification.
1. Introduction
Obesity is caused by an imbalance between energy intake
and energy expenditure that results in an enlarged growth
in adipose tissue that is generally harmful to health [1].
This burden of obesity on health extends across multiple
organ systems and diseases [2] since excessive fat deposition
is related to a higher prevalence of cardiovascular disease,
metabolic syndrome features, different type of cancers, and
other adverse clinical conditions [3]. In addition, obesity has
been associated with higher mortality rates [4].
In the last half century, the prevalence of human obesity
has risen dramatically all over the world [5]. High-income
countries are not the only ones affected by the epidemic, as
the condition is achieving alarming rates in the transition
world as well [6]. Thus, it has been reported that prevalence
of obesity has almost doubled from 6.4% in 1980 to 12.0% in
2008 in the entire world. Half of this rise occurred from 2000
to 2008 [7]. Furthermore, during 2013 worldwide obesity
prevalencewas estimated at 36.9% inmen and 38% inwomen,
while obesity-associated mortality and treatment expenses
make this disease the major global health challenge [8]. In
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addition to unhealthy habits (consumption of high-energy
yielding foods and low physical activity), the interaction
with genetic factors could be involved in this increased
prevalence [9]. Although human genome cannot change
in such short time, mechanisms involving epigenetics have
been proposed as a possible origin and/or development of
this increase [10]. Other factors have been suggested, such
as microbiota, increasing maternal age, greater fecundity
among obese people, assortative mating, sleep deprivation,
endocrine disruptors, pharmaceutical iatrogenesis, reduction
in variability of ambient temperatures, and intrauterine and
intergenerational effects [11].
At the tissue level, obesity is known to provoke a mild but
chronic inflammation state within the adipose tissue, leading
to multiple metabolic disorders if the condition persists [2].
Among the features that may lead to this inflammatory
response in obesity, it has been hypothesized that poorly
oxygenated adipose tissue may underlie the initiation and
development of this process [12, 13], although the relationship
between tissue oxygen partial pressure and adipose tissue
inflammatory process is still under debate [14–16]. Regard-
ing hypoxic conditions, several human studies have related
environmental hypoxia during expeditions at moderate- and
high-altitude conditions to a reduction of food intake [17, 18],
subsequent metabolic alterations, and weight loss [19, 20].
Similarly, our group found that rats exposed to normobaric
hypoxia reduced their food intake and, consequently, their
weight [21]. It is important to highlight that this hypobaric
hypoxia differs from the hypoxia described in obese adipose
tissue [22].
2. Inflammation and Obesity
Inflammatory processes are complex biological responses
orchestrated by tissues to combat injurious stimuli, as host
defense, tissue remodeling, and metabolic changes, in order
to maintain cell homeostasis [23]. More precisely, the inflam-
matory phenomena involve multiple specific cell processes
such as recruitment and activation of immune cells (leuko-
cytes, granulocytes, monocytes, lymphocytes, and dendritic
cells), stimulation of the production of different chemi-
cal bioactive mediators (such as cytokines, chemokines,
or prostanoids), regulation of signaling pathways involving
insulin, leptin, glucose, or lipids, and eventually epigenetic
regulation of the expression of important related genes as
nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-𝜅B/AP1) activity or IL-6 expression [24–26]. This
adaptive response can be instantaneous and short, which is
known as acute inflammation, or long and gradual as in
a chronic, mild inflammatory process. The latter has been
established as a main cause and/or a consequence of diverse
diseases that may need pharmacological interventions to
attenuate the cellular inflammatory routes such as diabetes,
cardiovascular diseases, and obesity [27].
Obesity itself is characterized by a state of mild chronic
inflammation in humans [28]. In fact, obesity-induced
inflammation has been described as metaflammation, that is,
a chronic and low-grade inflammatory response initiated by
excess nutrients in metabolic cells, where circulating levels
of an important number of inflammatory markers, such
as C-reactive protein (CRP), haptoglobin, Interleukin-1 (IL-
1), Interleukin-6 (IL-6), monocyte chemoattractant protein-1
(MCP-1), plasminogen activator inhibitor-1 (PAI-1), or tumor
necrosis factor-alpha (TNF-𝛼), are increased [1, 29, 30].
Additional studies suggest that adipose tissue inflammatory
state is orchestrated by monocyte/macrophage infiltration
and overproduction of proatherogenic cytokines, two sit-
uations that are related to the initiation and development
of several obesity-associated diseases such as atherosclerosis
and cardiovascular complications [31–33]. Indeed, about half
of the cells that make up adipose tissue of obese mice
were identified as macrophages, a feature that was asso-
ciated with low-grade systemic inflammation [33]. At this
point, it is important to note that there is a very specific
phenotype called “Metabolically Healthy Obese (MHO),”
which presents the following features: less visceral fat, less
infiltration of macrophages into adipose tissue, and smaller
adipocyte cell size, leading to a more favorable inflammatory
profile, although a recent meta-analysis has reported that
these subjects are at an increased risk of developing type 2
diabetes compared with their age-matched lean controls [34].
In this sense, diet has amain role in the inflammation [35, 36]
and oxidative stress-related outcomes [37, 38].
Certainly, several signaling pathways have been proposed
to explain the cause for the initiation of inflammatory
processes during obesity (Figure 1), including oxidative stress
[39], endoplasmic reticulum stress [40], and adipose tissue
hypoxia [13]. These features may provoke the release of
reactive molecules that can interact with proteins, lipids, or
DNA, causing cell damage/death and leading to nonspecific
proinflammatory effects [41]. These theories can explain
some aspects of inflammation and metabolic disorders in
obesity, but the link between obesity and these factors still
remains elusive [13, 42].
3. Hypoxia and Inflammation in
Adipose Tissue
Adipose tissue is constituted not only by adipocytes, but also
by a stromavascular cell fraction, which involves leukocytes
(includingmacrophages), T cells, and natural killer cells [43].
Some of these cells are a dominant source of inflammatory
cytokines and are, therefore, appropriate targets for the study
of mechanisms underlying hypoxia-induced inflammation
within this tissue [1, 44]. Inflamed tissues are often character-
ized by decreased oxygen availability and cells must be able
to maintain viability and proper function in strongly variable
microenvironments [45].
Indeed, hypoxia has been proposed as a key initiator
of adipokine dysregulation in obesity [22] by inducing the
expression of certain genes in adipocytes and macrophages
like TNF-𝛼, IL-1, IL-6, MCP-1, and PAI-1, macrophage
migration-inhibition factor (MIF), inducible-nitric oxide
synthase (iNOS), and others [41, 46–48]. Similarly, the
production of vascular endothelial growth factor (VEGF)
inducing a proangiogenic response is stimulated by hypoxia
in human and murine adipocytes [49, 50]. Furthermore, the
role of hypoxia and angiogenesis in tumor progression has
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Figure 1: Effects of obesity on adipose tissue. Oxidative stress, altered PO
2
, and endoplasmic reticulum stress are potential triggering factors
for metaflammation development. This chronic low-grade inflammation is associated with proinflammatory adipokines release and the
concomitant macrophages migration to metaflammation zone. And, then, positive feedback for proinflammatory signals is perpetuated in
the tissue which could be related to posterior metabolic disorders. IL-1𝛽: Interleukin-1𝛽; IL-6: Interleukin-6; TNF-𝛼: tumor necrosis factor-𝛼;
LEP: leptin; MS: metabolic syndrome; CVD: cardiovascular disease; IR: insulin resistance.
been described in several studies [51, 52]. In addition, it
has been reported that low O
2
availability may change the
expression of diverse proinflammatorymolecules [44, 50, 53–
56] and, also, inhibits enzymes related to lipid metabolism
such as Lipoprotein lipase by upregulating angipoietin-like
protein 4 (Angptl4) [57]. Nonetheless, different behavior
patterns are found depending on cellular origin, for example,
human or mouse (Figure 2).
Many of the aforementioned genes have been found to
be dependent on the activation of hypoxia-inducible factor-
1 alpha (HIF-1𝛼), the master transcriptional regulator of
hypoxia environment [56, 58, 59], since cellular adaptation
to hypoxia appears as a defense mechanism adopted by cells
to conserve the optimum oxygen concentration required for
vital metabolic functions [41], where activation of specific
and important transcription factors, such as HIF-1 or NF-
𝜅B, occurs [60]. The transcription factor HIF-1 is a het-
erodimer composed of an oxygen sensitive subunit HIF-
1𝛼 and a constitutively expressed subunit HIF-1𝛽 [41, 61,
62]. This protein is responsible for the induction of genes
that facilitate accommodation and survival from hypoxic
stress [63]. When cellular oxygen levels are normal, this
protein is immediately targeted for proteasome degrada-
tion [3]. However, under lower oxygen concentrations [64]
and mild oxidative stress (induced with H
2
O
2
) [65], as in
inflamed tissues, hydroxylation is inactivated, enabling the
binding of CREB-Binding Protein (CBP/p300) coactivator,
and therefore HIF-1𝛼 becomes stable, leading to the expres-
sion of HIF-1 target genes. Several studies have described
an increase in HIF-1𝛼 expression and protein levels in the
adipose tissue of dietary obese mice and ob/ob obese mice,
which are thought to suffer a low oxygen supply [3, 48].
Moreover, human primary preadipocyte cultures have shown
higher levels of HIF-1𝛼 mRNA and protein than mature
adipocytes [49]. These results suggest a posttranslational
regulation, where HIF-1𝛼 protein increases independently
of mRNA level in response to hypoxia in adipose tissue.
Interestingly, in human primary adipocytes, an elevation of
HIF-1𝛼 mRNA and protein levels has been described after 8
and 24 h of hypoxic exposure [50]. Other studies observed
an enhancement of Hif-1𝛼 mRNA and protein levels in 3T3-
L1 cells during adipogenesis [3, 66], whereas mRNA levels of
Hif-1𝛼 did not change in an assay performed in 3T3-L1 cells
under these conditions [46].
Although these changes are consistent with hypoxia,
they are not necessarily a direct response to low oxygen
concentrations, since other factors such as reactive oxygen
species (ROS) production and/or endoplasmic reticulum
stress are likely involved [1]. Furthermore, another scientific
group has suggested that, despite lower adipose tissue blood
flow, human adipose tissue may suffer hyperoxia in obese
subjects, explained apparently by lower oxygen consumption
within this organ [15], although this needs to be further
elucidated.
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3T3-L1 adipocytes
Human adipocytes
Adipose tissue C57BL/6J mice
↓ ADIPOQ [48]
↑ HIF-1𝛼 [3, 48]
↓ ADIPOQ [49, 50], IL-10 [44], MCP-1 [50, 55]
VEGF [49, 50, 55], TNF-𝛼 [44]
HIF-1𝛼 [88], IL-6 [44, 49, 50, 54], LEP [49, 50], MIF [49], PAI-1 [55],
↑ ANGPTL4 [55, 58, 103], APLN [50], DPP4 [57], GLUT-1 [41],
↓ ADIPOQ [48, 50, 53], PPAR-𝛾 [88], LEP [100]
LEP [56], MCP-1 [50], PAI-1 [53, 100], VEGF [50]
↑ APLN [96], ANGPTL4 [57], GLUT-1 [88], HIF-1𝛼 [3], IL-6 [100],
Figure 2: Effects of hypoxia on the secretion of key proteins in mice and human adipocytes and in adipose tissue of C57BL/6J mice (green
up arrow) increased and (red down arrow) decreased protein in response to hypoxia). ADIPOQ: adiponectin; ANGPTL4: Angiopoietin-
like protein 4; APLN: Apelin; DPP4: dipeptidyl peptidase-4; GLUT-1: Glucose Transporter 1; HIF-1𝛼: hypoxia-inducible factor-1𝛼; IL-6:
Interleukin-6; IL-10: Interleukin-10; LEP: leptin; MIF: macrophage migration inhibitory factor; MCP-1: monocyte chemoattractant protein-1;
PAI-1: plasminogen activator inhibitor-1; VEGF: vascular endothelial growth factor; TNF-𝛼: tumor necrosis factor-𝛼.
4. Treatments with Hyperoxia
Hyperoxia is referred to as a potentially harmful major
lifesaver [67]. Thus, oxygen is used in current medicine as a
treatment for several diseases such as chronic obstructive pul-
monary diseases, management of ulcers in diabetic patients,
and cerebral ischemia wounds and hypothesized and studied
as a tool for weightmanagement [46, 68, 69]. Nevertheless, an
excess of the exposure to oxygen in time and/or concentration
may lead to important deleterious effects [70, 71].
Hyperoxia increases the amount of dissolved oxygen in
blood with the subsequent action on tissue oxygenation and
mitochondrial metabolism [72]. These mechanisms explain
why oxygen is used as a therapy to optimize oxygen trans-
port capacity [73]. There are two clearly defined therapies
commonly used at the clinical level: hyperbaric oxygen
therapy (HBOT) and normobaric oxygen therapy (NBOT).
The former involves the inhalation of 100%O
2
in a chamber at
pressure greater than at sea level [74], while the latter involves
administering more than 21% O
2
at normal atmospheric
pressure.
Over the past years, multiple studies have documented
NBOTandHBOT tohave important clinical applications (see
the following).
Experimental and nonapproved claimed beneficial effects
of hyperoxia treatment are as follows:
Anti-inflammatory effect [75].
Better control of blood glucose levels [76].
Cytoprotection in chemotherapy side effects [77].
Decreased inflammatory pain [78].
Decreased ischemic stroke mortality and comorbidi-
ties [79–81].
Enhanced survival and regeneration of fat grafting
[82].
Improved glucose utilization by the brain [83].
Increased angiogenesis [84].
Increased insulin sensitivity [85].
Neuroprotection in hypoxic-ischemic injury [86, 87].
Neuroprotection in traumatic brain injury [88].
Terminated migraine headache pain [89].
Tumour control and decreased mortality and recur-
rence [90].
Wound healing [91–94].
For example, oxygen therapy has demonstrated effective-
ness in the treatment of acutely ischemic brain tissue, in
acute ischemic stroke, in the amelioration of pathological
brain infarct volumes, and in the enhanced survival and
regeneration of fat grafting, among others [71, 79–82, 95,
96]. The acting mechanisms in this scenario have been
attributed, in part, to an increase in the aerobic metabolism
and angiogenesis processes, leading to an improvement of the
natural vascularization phenomena [84]. Moreover, several
investigations have shown the beneficial effects of HBOT
on wound healing [91–93], relieving migraine headaches
[90], and local tumour control, mortality, and recurrence for
cancers of the head, neck, and uterine cervix [89, 90].
Regarding metabolic alterations, there is evidence that
HBOT and NBOT are able to attenuate systemic inflam-
mation. On a zymosan-induced generalized inflammation
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mouse model, 80% survival rate of mice treated with 100%
O
2
with respect to control has been reported [97]. Moreover,
zymosan mice treated with 100% O
2
showed significant
reductions in the expression of inflammatory cytokines and
little distortion in overall tissue architecture compared to the
animals maintained in room air. Finally, O
2
treated mice also
presented significant improvements in serum alanine amino-
transferase (ALT) test, aspartate aminotransferase (AST) test,
and creatinine. Importantly, amelioration of inflammation
and pain was also obtained in carrageenan-induced rats
exposed to HBOT [78]. Taken together, these researches
clearly illustrate that 100% O
2
treatment may improve organ
structure and function as well as suppress the inflammatory
cascade response, suggesting the possibility of oxygen treat-
ment to be used in chronic cases of inflammation.
Furthermore, there is evidence that HBOT reduces blood
glucose levels in patients with type 2 diabetes and hyperten-
sion [76]. This beneficial outcome may be due to an increase
in glucose utilization by the brain, a feature that has been
documented after HBOT exposure in rats [83], while insulin
has also been described to have important actions in these
circumstances. Indeed, a recent study has shown that HBOT
(100% O
2
; 2.0 ATA for 2 h) was able to increase insulin
sensitivity in both healthy subjects and obese individuals with
type 2 diabetes. Of note, this positive effect, which authors
state to be equivalent to that found after moderate weight
loss, was observed within 3 days of HBOT and maintained
for 30 sessions [85]. However, the implicatedmechanisms are
unknown and require further elucidation.
Interestingly, various studies have provided evidence for
an analogous beneficial effect under hypoxic conditions,
on glucose homeostasis and adipose tissue inflammation,
in rodents [98, 99], and on insulin sensitivity in diabetic
patients [100] and obese subjects [101]. Furthermore, several
studies have also reported healthier values of blood pressure
for humans that have exercised under hypoxia [102–104].
Nevertheless, other researchers have found no significant
differences in obese people in blood glucose levels [105] and
in obese people suffering sleep apnea-hypopnea syndrome in
the blood levels of glucose, insulin, and relevant inflamma-
tory parameters [104].
In addition, Obstructive Sleep Apnea (OSA), which
appears to be a direct cause and a direct consequence of
weight gain [106], is benefitted by the use of hyperoxia
primarily based on its ability to reduce loop gain (LG),
defined as the ratio of the ventilatory overshoot to the
preceding reduction in ventilation [107].
Overall, these studies evidence that oxygen exposure has
also important positive effects at a systemic level, being able
to ameliorate inflammation andmetabolic disruptions, which
are features commonly presented in obesity. Considering that
oxygen treatment may also be harmful due to proinflam-
matory outcomes, next steps should focus on investigating
the delicate balance between oxygen protection and toxicity,
determining the optimal duration, partial pressure, and tim-
ing of treatment, among others. In this sense, it is interesting
to note that weight reduction increases partial oxygen arterial
blood pressure (PaO
2
) and, also, that morbidly obese women
seem to have at rest a better gas exchange [108].
5. Studies Related to Hyperoxia and Its
Associated Molecular Effects
Several studies have reported that high oxygen concentra-
tions can modulate mRNA expression of several genes and
related protein secretion (some genes of interest for the topic
of this review are listed in Table 1). For example, clinical
and experimental studies have demonstrated that increasing
oxygen concentrations in hypoxic and/or ischemic wounds
accelerate the healing process by increasing blood vessels
growth [94]. Specifically, this study observed an increase of
VEGF synthesis in wounds of Sprague-Dawley rats exposed
to HBOT (100% O
2
for 90 minutes twice daily for 7 days).
Moreover, after 5 h of HBOT (90min at 97.5% O
2
at 2.4
ATA) nineteen genes involved in adhesion, angiogenesis,
inflammation, and oxidative stress were downregulated [109].
Notably, only angiogenin gene expression (which promotes
both angiogenesis and nitric oxide production) was upreg-
ulated. This situation induced a decrease in endothelial Il-
8 mRNA expression and further protein secretion, leading
to an alleviation of inflammatory processes during chronic
wound healing. Indeed, a study performed in mice found
out that the cholinergic pathway seems to be the underlying
mechanism by which the HBOT has an anti-inflammatory
role [110]. On the other hand, neonatal rats exposed to NBOT
had long term adverse effects related to cardiovascular and
renal dysfunctions in the adulthood [111].
Regarding lung injury, a study carried out in alveo-
lar macrophages obtained from children with interstitial
lung disease observed a decrease in TNF-𝛼, IL-1, and IL-6
expression and an increase in Interleukin-8 (IL-8) expression
after hyperoxia exposure [75]. These data confirmed that
hyperoxia induces changes in mRNA and protein levels in
macrophages. The effect of HBOT and NBOT was analysed
in Sprague-Dawley rat newborns exposed to 8% O
2
for 2 h.
One hour after hypoxia exposure mice were treated with
100%O
2
under normobaric or hyperbaric conditions. Results
confirmed that a single administration of HBOT or NBOT
dose dependently reduced the hypoxic-ischemic-induced
elevation of HIF-1𝛼 [86]. Indeed, oxygen regulates the degra-
dation of HIF-1𝛼, and the HIF-1𝛼-depending gene regulation
is responsible for several different genetic expressions such as
erythropoietin (EPO) and VEGF. These genes are frequently
expressed in parallel, leading to the possibility that HIF
induction could stimulate immune response by inflammatory
cells [122]. For example, after hyperoxia treatment, VEGF
downregulation could decrease tumour angiogenesis, and the
induction of EPO-expression could provide cytoprotection,
processes that could be deleterious for cancer cells while
helping nonmalignant cells (at least neural and cardiac) to
be protected from the side effects of chemotherapy [77].
Nonetheless the influence of HBOT onHIF isoforms expres-
sion in other cell types or tissues is variable [123]. In this
regard, no changes were observed in Hif-1𝛼 gene expression
modifications in 3T3-L1 adipocytes exposed to 95% O
2
[46].
Thereby further experiments need to be performed, always
bearing inmind thatHIF-1𝛼mRNAexpression is particularly
unstable.Therefore, data related to HIF-1𝛼mRNA expression
should be interpreted with prudence.
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Table 1: Results of the responses (mRNA, protein, and ROS production) to different oxygen exposures in different experimental models.
Gene Model/tissue Treatment Duration mRNA Prot. Authors
Angptl4 3T3-L1/adipocyte culture 95% O2 24 h ↓ ND [46]
Hif-1𝛼
3T3-L1/adipocyte culture 95% O2 24 h ns ND [46]
Male C56BL/6J mice/brain 50% O2 1 week ns ND [112]
Sprague-Dawley rat/brain with IH
damage
NBOT/HBOT 2 h ND ↑↑/↑ [86]
Il-1
Sprague-Dawley rat/lung 90% O2 10 h, on postnatal day 14 ND ↑ [113]
Human/alveolar macrophages primary
culture (ILD)
95% O
2
48 h ↓ ND [75]
C57BL/6J mice/lung >95% O2 3 days ↑ ND [114]
Il-6
Sprague-Dawley rat/lung 90% O2 10 h, on postnatal day 14 ND ↑ [113]
3T3-L1/adipocyte culture 95% O2 24 h ↑ ND [46]
Male C57BL/6J WT mice and db/db
mice/BAL
100% O
2
84 h ND ↑ [115]
Human/alveolar macrophages primary
culture (ILD)
95% O
2
48 h ↓ ND [75]
C57BL/6J mice/lung >95% O2 3 days ND ↓ [114]
Il-8
Human/UVEC culture with chronic
wound
97.5% O
2
90󸀠 ↓ ↓ [109]
Human/alveolar macrophages primary
culture (ILD)
95% O
2
48 h ↑ ND [75]
Leptin
3T3-L1/adipocyte culture 95% O2 24 h ns ND [46]
Male C57BL/6J WT mice and db/db
mice/BAL
100% O
2
84 h ND ↑ [115]
Female C57BL/6 ob/ob mice/adipose
tissue
100% O
2
72 h ↑ ND [116]
Tnf-𝛼
Sprague-Dawley rat/lung 90% O2 10 h, on postnatal day 14 ND ↑ [113]
Male C57BL/6J WT mice and db/db
mice/BAL
100% O
2
84 h ND ↑ [115]
Female 57BL/6 ob/ob mice/adipose tissue 100% O2 72 h ↓ ns [116]
Human/alveolar macrophages primary
culture (ILD)
95% O
2
48 h ↓ ND [75]
Sprague-Dawley rat/lung macrophages
primary culture
100% O
2
90󸀠 ND ↑ [117]
C57BL/6J mice/lung >95% O2 3 days ND ↑ [114]
Vegf
Sprague-Dawley rat/lung 90% O2 10 h, on postnatal day 14 ND ↓ [113]
Male C56BL/6J mice/brain 50% O2 1 week ↓ ND [112]
Sprague-Dawley rat/wound fluid 100% O2 90
󸀠 twice daily for 7 days ND ↑ [94]
Sprague-Dawley rat/liver 95% O2 2 weeks, newborn ND ↓ [118]
ROS
3T3-L1/adipocyte culture 95% O2 24 h ↑ [46]
Sprague-Dawley rat/carotid body and
PG/NG complex
95% O
2
4 h ↑ [119]
Male Sprague-Dawley rats/lung capillary
endothelial cells
70% O
2
90󸀠 ↑ [120]
C57BL/6J mice/liver with ischemia 60% O2 24 h ↑ [121]
Angptl4: Angiopoietin-like 4; Hif-1𝛼: hypoxia-inducible factor-1𝛼; Il-1: Interleukin-1; Il-6: Interleukin-6; Il-8: Interleukin-8; Tnf-𝛼: tumor necrosis factor-𝛼;
Vegf : vascular endothelial growth factor; ROS: reactive oxygen species; BAL: bronchoalveolar lavage; CIH: chronic intermittent hypoxia; ILD: interstitial lung
disease; UVEC: umbilical vein endothelial cells; ND: no data; ns: no significant difference detected.
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Concerning O
2
treatment and adipose tissue, our group
was the first to evaluate the effect of hyperoxia (95% O
2
;
24 or 48 h) on 3T3-L1 adipocytes. In these experiments, a
strong proinflammatory response was observed, as demon-
strated by the release of intra- and extracellular ROS and
the upregulation of proinflammatory adipokines such as Il-
6 and Mcp-1 [46, 69]. A strong correlation between Mcp-
1 mRNA expression and ROS release was also found [46],
a result that is in accordance with other studies showing
that ROS production could increase Mcp-1 expression [124].
However, other interesting outcomes were observed, such
as upregulation of peroxisome proliferator-activated receptor
gamma (Ppar-𝛾) signalling [46]. This finding is in agreement
with the above-mentioned studies linking O
2
therapy and
amelioration of insulin sensitivity and suggests that adipose
tissue may also contribute to this feature. Finally, hyperoxia
caused a decrease in the expression of Angiopoietin-like 4
(Angptl4) [46, 69], which is a protein that regulates plasma
triacylglycerides metabolism by inhibiting lipoprotein lipase
[125]. In this context, some authors have proposed that
elevated ANGPTL4 expression might be involved in hyper-
triglyceridemia in patients with insulin resistance [126] and
other hypoxic conditions [103]. Thus, a downregulation in
Angptl4 expression, as it occurs with hyperoxia in 3T3-L1
adipocytes, might contribute to ameliorating these metabolic
disorders. Furthermore, glycerol and lactate release were
increased and decreased, respectively, under an elevated
oxygen exposure in 3T3-L1 adipocytes [46, 69], and in male
Wistar rats fed with control diet a similar effect on lactate
was found (Pablo Quintero, Pedro Gonza´lez-Muniesa, and
J. Alfredo Martinez, unpublished results). Lactate inhibits
lipolysis in adipose tissue by mediating, through GPR81,
the antilipolytic action of insulin [127], and therefore a
reduction in lactate might be considered beneficial against
the appearance and development of complications associated
with obesity. From these experiments, it can be gathered
that hyperoxia activates a pernicious proinflammatory status
although it seems to have beneficial effects on glucose and
lipid metabolism [46, 69]. In contrast with this, a study by
Hodson et al. 2013 has reported in humans an inverse rela-
tionship between the amount of lactate released by adipose
tissue and the BMI of the subject [16]. Interestingly, hyperoxia
in mice leads to weight loss and an increase in leptin, an
adipokine involved in the regulation of food intake, although
it seems that this weight loss is not dependent on leptin
[116]. Intriguingly, a similar result was found in mice after
21 days being exposed to chronic hypoxia (8% O
2
), in which
these animals lose weight and adipose tissue mass and size,
and leptin concentrations were decreased [101]. Nevertheless,
more studies are needed to obtain a better understanding
of these mechanisms and, more importantly, to determine
the optimum duration and timing of treatment to avoid
undesired effects. Moreover, some results are contradictory
or not comparable due to the wide variety of concentrations
and/or duration of the exposures and also the experimental
models and analyzed tissues. For instance, the gene expres-
sion of the proinflammatory cytokine IL-8 was increased in
alveolar macrophages from interstitial lung disease treated
with 95%O
2
for 48 h [109], while decreased in chronic wound
of umbilical vein endothelial cells treated with 95% O
2
for 90
minutes [75].These data suggest that more research is needed
regarding the different tissues, experimentalmodels, and type
of treatments to elucidate the benefits and disadvantages of
hyperoxia therapy.
6. Conclusions and Future Directions
Oxygen homeostasis is of fundamental importance to the cell
and tomaintain equilibriumwithin the existing complex rela-
tionships between oxygen concentration, energymetabolism,
acid-base status, redox state, and the control of cell growth
and proliferation [63].The studies herein reviewed evidenced
that an abnormal level of oxygen partial pressure in expanded
adipose tissue may be a triggering factor for the release
of inflammatory mediators. Moreover, several studies have
demonstrated that treatment with hyperoxia/hypoxia may
play an important role in the regulation of inflammatory
responses andmetabolic disorders, such as insulin resistance.
Furthermore, aerobic exercise, which increases body general
oxygenation, seems to play a main role in visceral adipose
tissue reduction [128].
Taking into account the information presented in this
review and further preliminary experimental data, we put for-
ward some questions in order to address future investigations
about metaflammation treatment with hyperoxia exposure:
(1) Which is the origin of proinflammatory signalling in
obesity and its role in obesity-associated manifesta-
tions?
(2) Would HIF-1𝛼 signalling be a possible therapeutic
target in an obesity context?
(3) Which are the possible effects of oxygen therapy as an
obesity treatment, particularly on metaflammation?
Yet, more studies are needed to shed more light on
the molecular effects of oxygen (hyperoxia or hypoxia) and
the concentration available of this gas in various fat depots
from humans with different phenotypes, for example, those
suffering obesity with or without insulin resistance. Maybe
one day this therapy could be used as an advantageous
tool to improve various diseases concerning inflammatory
conditions.
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